{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE289nnn/GSE289101/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289101"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Human CD14+ monocytes from volunteers before and after a 3 hours, 24 hours and 120 hours-period of methotrexate intake. METOMAC trial","description":"Arthritis patients receive a weekly low-dose of Methotrexate (MTX) as a first-line disease modifying anti-rheumatic drug. Following low-dose administration, MTX typically reaches peak plasma concentrations after 1-2 hours, and almost completely disappears from the circulation by 24 hours. However, the kinetics of the anti-inflammatory action of MTX in monocytes after the initial dose is unknown.To address this issue, we carried out a phase I clinical trial (METOMAC) in which peripheral blood from 6 healthy donors receiving a single dose of MTX was analyzed at distinct time points after drug intake (3 hours, 24 hours, 120 hours). RNA-seq on monocytes isolated at the distinct timepoints was determined.","dates":{"publication":"2026/04/01"},"accession":"GSE289101","cross_references":{"GSM":["GSM8783727","GSM8783738","GSM8783737","GSM8783726","GSM8783729","GSM8783728","GSM8783739","GSM8783723","GSM8783734","GSM8783733","GSM8783725","GSM8783736","GSM8783735","GSM8783724","GSM8783730","GSM8783741","GSM8783740","GSM8783732","GSM8783731","GSM8783742"],"GPL":["23227"],"GSE":["289101"],"taxon":["Homo sapiens"],"PMID":["[41840229]"]}}